Tisdag 22 Juli | 08:16:30 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-10-22 07:50 Kvartalsrapport 2025-Q3
2025-07-18 - Kvartalsrapport 2025-Q2
2025-06-11 - Extra Bolagsstämma 2025
2025-04-30 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2025-04-29 - Årsstämma
2025-04-29 - Kvartalsrapport 2025-Q1
2025-02-13 - Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-08-15 - Kvartalsrapport 2024-Q2
2024-05-23 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2024-05-22 - Årsstämma
2024-05-02 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-08-17 - Kvartalsrapport 2023-Q2
2023-06-02 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2023-06-02 - Årsstämma
2023-05-04 - Kvartalsrapport 2023-Q1
2023-03-24 - Extra Bolagsstämma 2023
2023-03-08 - Bokslutskommuniké 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-10-03 - Extra Bolagsstämma 2022
2022-08-24 - Kvartalsrapport 2022-Q2
2022-06-03 - X-dag ordinarie utdelning VIMIAN 0.00 SEK
2022-06-02 - Årsstämma
2022-05-24 - Kvartalsrapport 2022-Q1
2022-03-09 - Bokslutskommuniké 2021
2021-11-26 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Vimian Group är en koncern verksamma inom djurhälsa. Bolaget levererar via sina dotterbolag läkemedel och tekniska lösningar till veterinärer, laboratorier och husdjursägare. Produkterna inkluderar exempelvis läkemedel med tillhörande klinisk forskning samt digitala plattformar för veterinärkliniker. Bolaget är verksamma på en global nivå med huvudkontor i Stockholm.
2025-07-17 18:30:00

Today, Vimian Group AB (publ) (“Vimian”) announces that Patrik Eriksson steps down from his position as CEO of Vimian with immediate effect. Carl-Johan Zetterberg Boudrie, CFO of Vimian, is appointed interim CEO. The recruitment process for a new CEO will be initiated immediately.

“Viman enjoys a strong position as a global leader in niches of animal health with significant unmet medical needs and attractive growth prospects. The potential for Vimian in the global animal health market is significant and the Board of Directors has agreed that a different leadership is in the best interest of the company and its shareholders for the long term. Focus will be on accelerating the execution of Vimian’s strategic pillars of driving profitable organic and M&A driven growth, leveraging the scale and advantages of being a global group while building on the strong entrepreneurial culture in the company. The Board is confident in the company’s strategy and financial targets and our ability to successfully execute on our business plans across our four segments”, says Magnus Welander, Chairman of the Board in Vimian and continues:

“On behalf of the Board, I would like to thank Patrik for his contributions to Vimian’s development. Under his tenure the company has delivered strong growth, entered new fast-growing market niches and completed the list change to the main market”.

Additional changes to the Vimian Group executive management team

Effective today, Alireza Tajbakhsh will, in addition to his current role as Head of Vimian’s Veterinary Services segment, assume interim operational responsibility for Vimian’s MedTech segment. He succeeds Guy Spörri who has decided to leave the company at year-end. Furthermore, Bart Bremer, Chief People Officer, is appointed member of Vimian’s executive management team.

All the above changes are effective today 17 July 2025.

Interim report and conference call

Vimian Group AB will publish its Interim Report for the second quarter of 2025 on Friday, 18 July, at 07.45 (CET). A conference call will be organised on the same day at 09.00 (CET) where Magnus Welander, Chairman of the Board, and Carl-Johan Zetterberg Boudrie, CFO and interim CEO, will participate.

To attend the telephone conference:
Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the telephone conference.
https://events.inderes.com/vimian-group/q2-report-2025/dial-in

To attend the webcast:
Link: https://vimian-group.events.inderes.com/q2-report-2025